CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced the presentation of new data on its lead SER-109 Phase 2 microbiome program for multiply recurrent Clostridium difficile infection (CDI), and its SER-262 preclinical program for primary CDI at the American Society for Microbiology annual meeting, ASM Microbe 2016. New data highlighted, for the first time, the design characteristics of SER-262, an Ecobiotic® rationally-designed, fermented microbiome therapeutic candidate for primary CDI. SER-262, an oral capsule, is a synthetic product derived by a manufacturing process that does not require human donor material.
